Skip to main content
OpenTrials
Completed

NCT Number: NCT00539149

Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children

This clinical trial was conducted in a population where tympanic membrane perforation occurs in 60% infants in the first year of life. Nasopharyngeal colonisation (nasal contamination) with pathogenic bacteria occurs within weeks of life and predicts persistent middle ear infection throughout childhood. The trial aimed to assess whether twice daily antibiotics commencing at first detection of middle ear effusion would cure the infection and/or prevent disease progression, compared to placebo.

The study was conducted in three remote Aboriginal communities in the Northern Territory of Australia. The annual birth cohort was 45.

Aboriginal infants were seen as soon as possible after birth, and at 2 weekly intervals until middle ear effusion was detected by pneumatic otoscopy and tympanometry. Following consent, infants were randomised to either amoxycillin(50 mg/kg/d BD) or placebo equivalent for up to 24 weeks, or until normal middle ear status was detected at 2 consecutive monthly scheduled examinations. At monthly examinations the infant also had a general health check, parents were interviewed, child's medical record was reviewed, and nasopharyngeal swabs were collected.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 12 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Menzies School of Health Research

Darwin, Northern Territory, 0811, Australia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Australian Aboriginal
  • Living in participating remote community
  • Less than 12 months of age

Exclusion criteria

  • Less than 32 weeks gestation
  • Chronic condition requiring continuous antibiotic
  • Ear, nose or throat abnormality

Treatment and study plan

Amoxycillin

Drug

50 mg/kg/day twice daily

Placebo equivalent to amoxycillin

Drug

50 mg/kg/d twice daily

Primary outcomes

  1. Proportion of children with middle ear effusion

    Time frame: end of intervention

  2. Proportion of study visits at which middle ear effusion detected

    Time frame: during intervention

Secondary outcomes

  1. Proportion of infants with tympanic membrane perforation

    Time frame: end of intervention

  2. Proportion of study visits with tympanic membrane perforation

    Time frame: during intervention

  3. Proportion of infants with nasopharyngeal colonisation with resistant Streptococcus pneumoniae

    Time frame: end of intervention

  4. proportion of infants withdrawn from study due to intervention adverse events

    Time frame: end of intervention

Sponsors and collaborators

Lead sponsor

Menzies School of Health Research

Other

Collaborators

  • National Health and Medical Research Council, Australia

Registry information

Official study title

Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.

Acronym: COMIT1

Important dates

Study start
1996
Study completion
2001
First posted
Oct 4, 2007
Registry last updated
May 24, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.